CO4770976A1 - Derivados de 5-heteroaril-2,3(1h,4h)-quinoxalinadiona . . - Google Patents

Derivados de 5-heteroaril-2,3(1h,4h)-quinoxalinadiona . .

Info

Publication number
CO4770976A1
CO4770976A1 CO97012901A CO97012901A CO4770976A1 CO 4770976 A1 CO4770976 A1 CO 4770976A1 CO 97012901 A CO97012901 A CO 97012901A CO 97012901 A CO97012901 A CO 97012901A CO 4770976 A1 CO4770976 A1 CO 4770976A1
Authority
CO
Colombia
Prior art keywords
alkyl
alkoxy
aryl
halo
independently selected
Prior art date
Application number
CO97012901A
Other languages
English (en)
Inventor
David John Bull
Christopher Lee Carr
Michael Jonathan Fray
Elisabeth Colette
Charles Eric Mowbray
Alan Stobie
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of CO4770976A1 publication Critical patent/CO4770976A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

La invención proporciona compuestos de la fórmula I:y las sales farmacéuticamente aceptables de los mismos,en la queR es un grupo heteroarilo de anillo de 5 miembros que contiene 3 ó 4 heteroátomos de nitrógeno, que está unido al anillo de quinoxalinadiona mediante un átomo de carbono o nitrógeno del anillo, o es un grupo heteroarilo de anillo de 6 miembros que contiene de 1 a 3 heteroátomos de nitrógeno, que está unido al anillo de quinoxalinadiona por un átomo de carbono del anillo, estando cualquiera de dichos grupos opcionalmente condensado con benceno y opcionalmente sustituido, incluyendo la parte condensada con benceno, con 1 ó 2 sustituyentes seleccionados cada uno, independientemente, entre alquilo C1 -C4 , alquenilo C2 -C4 , cicloalquilo C3 -C7 , halo, hidroxi, alcoxi C1 -C4 , cicloalquiloxi C3 -C7 , -COOH, alcoxicarbonilo C1 -C4 , -CONR3 R4 , -NR3 R4 , -S(O)p (alquilo C1 -C4 ), -SO2 NR3 R4 , arilo, ariloxi, arilalcoxi(C1 -C4 ) y het, estando dicho alquilo C1 -C4 opcionalmente sustituido por cicloalquilo C3 -C7 , halo, hidroxi, alcoxi C1 -C4 , haloalcoxi(C1 -C4 ), cicloalquiloxi C3 -C7 , cicloalquil C3 -C7 , alcoxi(C1 -C4 ), -COOH, alcoxicarbonilo C1 -C4 , -CONR3 R4 , -NR3 R4 , -S(O)p (alquilo C1 -C4 ), -SO2 (arilo), -SO2 NR3 R4 , morfolino, arilo, ariloxi, arilalcoxi(C1 -C4 ) o het, y estando opcionalmente sustituido dicho alquenilo C2 -C4 por arilo; R1 y R2 se seleccionan cada uno, independientemente, entre H, fluoro, cloro, bromo, alquilo C1 -C4 y haloalquilo (C1 -C4 );R3 y R4 se seleccionan cada uno, independientemente, entre H y alquilo C1 -C4 o, cuando se toman conjuntamente, son alquileno C5 -C7 ; p es 0, 1 ó 2;...
CO97012901A 1996-03-09 1997-03-10 Derivados de 5-heteroaril-2,3(1h,4h)-quinoxalinadiona . . CO4770976A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9605027.3A GB9605027D0 (en) 1996-03-09 1996-03-09 Quinoxalinediones

Publications (1)

Publication Number Publication Date
CO4770976A1 true CO4770976A1 (es) 1999-04-30

Family

ID=10790134

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97012901A CO4770976A1 (es) 1996-03-09 1997-03-10 Derivados de 5-heteroaril-2,3(1h,4h)-quinoxalinadiona . .

Country Status (42)

Country Link
US (1) US6376490B1 (es)
EP (1) EP0885212B1 (es)
JP (1) JP3110467B2 (es)
KR (1) KR100288099B1 (es)
CN (1) CN1103770C (es)
AP (1) AP767A (es)
AR (1) AR006119A1 (es)
AT (1) ATE208773T1 (es)
AU (1) AU717972B2 (es)
BG (1) BG63340B1 (es)
BR (1) BR9707851A (es)
CA (1) CA2248366C (es)
CO (1) CO4770976A1 (es)
CZ (1) CZ292792B6 (es)
DE (1) DE69708269T2 (es)
DK (1) DK0885212T3 (es)
DZ (1) DZ2188A1 (es)
EA (1) EA001730B1 (es)
ES (1) ES2163742T3 (es)
GB (1) GB9605027D0 (es)
HN (1) HN1998000034A (es)
HR (1) HRP970132A2 (es)
HU (1) HUP9900975A3 (es)
ID (1) ID18112A (es)
IL (1) IL125491A (es)
IS (1) IS4811A (es)
MA (1) MA26422A1 (es)
NO (1) NO984058L (es)
NZ (1) NZ331060A (es)
OA (1) OA10850A (es)
PE (2) PE43398A1 (es)
PL (1) PL329032A1 (es)
PT (1) PT885212E (es)
SI (1) SI0885212T1 (es)
SK (1) SK283467B6 (es)
TN (1) TNSN97044A1 (es)
TR (1) TR199801782T2 (es)
TW (1) TW454004B (es)
UY (1) UY24482A1 (es)
WO (1) WO1997032873A1 (es)
YU (2) YU39698A (es)
ZA (1) ZA971987B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ336842A (en) * 1997-02-27 2000-05-26 Pfizer Process of making quinoxalinediones to produce antagonistic effect at NMDA receptors
AP982A (en) 1997-02-27 2001-07-16 Pfizer Quinoxalinediones.
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
DE10005150A1 (de) * 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
RU2002133666A (ru) * 2000-05-19 2007-05-10 Мерк Патент ГмбХ (DE) Производные триазола
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
MY145368A (en) * 2004-01-13 2012-01-31 Nissan Chemical Ind Ltd Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
CN1926647B (zh) 2004-02-06 2010-04-14 国立大学法人山口大学 储能装置用电极及其制造方法
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
US20060211739A1 (en) * 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2150248A4 (en) * 2007-01-16 2011-06-29 Univ Johns Hopkins GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN110724124A (zh) * 2007-05-17 2020-01-24 株式会社半导体能源研究所 三唑衍生物
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CA2900300A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN111548320B (zh) * 2019-10-09 2023-03-24 贵州大学 一类1,3,4-噁二唑酰肼类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656154B2 (en) * 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
NZ336842A (en) * 1997-02-27 2000-05-26 Pfizer Process of making quinoxalinediones to produce antagonistic effect at NMDA receptors

Also Published As

Publication number Publication date
IS4811A (is) 1998-07-27
HRP970132A2 (en) 1998-06-30
BG63340B1 (bg) 2001-10-31
TR199801782T2 (xx) 1998-12-21
DZ2188A1 (fr) 2002-12-02
SI0885212T1 (en) 2002-02-28
EP0885212A1 (en) 1998-12-23
PT885212E (pt) 2002-02-28
EP0885212B1 (en) 2001-11-14
NO984058L (no) 1998-11-06
BR9707851A (pt) 1999-07-27
PE43398A1 (es) 1998-08-29
DK0885212T3 (da) 2002-03-25
EA001730B1 (ru) 2001-08-27
DE69708269T2 (de) 2002-07-25
SK121498A3 (en) 2000-10-09
KR100288099B1 (ko) 2001-05-02
JPH11506123A (ja) 1999-06-02
IL125491A0 (en) 1999-03-12
CA2248366A1 (en) 1997-09-12
CA2248366C (en) 2002-06-04
TW454004B (en) 2001-09-11
OA10850A (en) 2001-08-16
AU717972B2 (en) 2000-04-06
HUP9900975A3 (en) 2001-12-28
BG102760A (en) 1999-09-30
AR006119A1 (es) 1999-08-11
ES2163742T3 (es) 2002-02-01
GB9605027D0 (en) 1996-05-08
YU41199A (sh) 2001-09-28
CN1213369A (zh) 1999-04-07
SK283467B6 (sk) 2003-08-05
ATE208773T1 (de) 2001-11-15
UY24482A1 (es) 2000-09-29
CN1103770C (zh) 2003-03-26
PE58199A1 (es) 1999-06-11
AU2023197A (en) 1997-09-22
NO984058D0 (no) 1998-09-03
TNSN97044A1 (fr) 2005-03-15
KR19990087614A (ko) 1999-12-27
JP3110467B2 (ja) 2000-11-20
DE69708269D1 (de) 2001-12-20
ZA971987B (en) 1998-09-07
HN1998000034A (es) 1999-02-09
AP767A (en) 1999-09-29
HUP9900975A2 (hu) 1999-07-28
ID18112A (id) 1998-03-05
CZ286498A3 (cs) 1999-07-14
CZ292792B6 (cs) 2003-12-17
US6376490B1 (en) 2002-04-23
YU39698A (sh) 1999-03-04
NZ331060A (en) 2000-01-28
EA199800702A1 (ru) 1999-04-29
IL125491A (en) 2003-07-06
PL329032A1 (en) 1999-03-01
WO1997032873A1 (en) 1997-09-12
MA26422A1 (fr) 2004-12-20
AP9700947A0 (en) 1997-04-30

Similar Documents

Publication Publication Date Title
CO4770976A1 (es) Derivados de 5-heteroaril-2,3(1h,4h)-quinoxalinadiona . .
AR011623A1 (es) Compuestos de sulfonamidas, procedimiento para prepararlos y composiciones farmaceuticas para potenciar las funciones de los glutamatoreceptores enmamiferos.
CO4960658A1 (es) Derivados de acidos ariloxiarilsulfonilamino hidroxamicos
CO5160347A1 (es) Derivados de acido carbamico
DK0427549T3 (da) Heterocykliske oxy-phenoxyeddikesyrederivater og deres anvendelse som herbicider
DK1258484T3 (da) Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler
EP0040639A4 (en) ISOXAZOLE DERIVATIVES.
ATE103592T1 (de) Carbamoylpyrrolidonderivate, ihre verwendung und herstellung.
KR830005162A (ko) 색소형성 퀴나졸린
NO900487L (no) Fremgangsmaate for fremstilling av tetrahydrobenzimidazolderivater.
ES2039221T3 (es) Procedimiento para producir derivados de piridazinona.
AR008287A1 (es) Composicion herbicida que comprende compuestos de pirazol sustituidos y metodo de aplicacion de los mismos
ES2153424T3 (es) Heterociclocromenos fotocromicos.
AR245699A1 (es) Compuestos derivados de n'-alquil-n,n'-diacilhidrazinas insecticidamente activos y composicion que los comprende.
IE37817B1 (en) 3-acylhydrazonomethyl rifamycin sv
CO4940478A1 (es) Derivados de 1-(2-acilimidazol-1-ilalquil) quinuclidino
AR001113A1 (es) 1-alqueniltetrazolinonas un procedimiento para su preparación composiciones herbicidas y procedimientos para su preparación procedimiento para combatir malas hierbas y compuestos intermediarios
DK214580A (da) 2-aminopropanalacetaler fremgangsmaade til fremstilling deraf anvendelse deraf som fungicider og fremgangsmaade til fremstilling af substituerede aniliner
DE69624459T2 (de) Kondensierte indan-derivate und ihre salze
NO982549L (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav
ATE122040T1 (de) Pestizide heterozyklische verbindungen.
FI902775A0 (fi) Aryloxi-, aryltio-, heteroaryloxi-, heteroaryltio-alkylenderivat av aminer.
FI903995A0 (fi) Imidazolyl- och pyridylderivat av fenylsubstituerade 1,4-dihydropyridiner och foerfarande foer framstaellning daerav.
SE7701843L (sv) Forfarande for framstellning av nya derivat av ditiepino-(1,4)(2,3-c)-pyrrol
IL84300A (en) Herbicidal compositions containing 1-(2-(hetero)-arylsulphonylcarbanoyl)-2-pyrazoline derivatives,certain such novel compounds and their preparation